These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7198457)

  • 41. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
    Bailey MJ; Dickinson RG
    Chem Res Toxicol; 1996; 9(3):659-66. PubMed ID: 8728513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Toxic myopathy due to hypolipemic agents].
    Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
    Therapie; 1990; 45(4):360. PubMed ID: 2399525
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE; Kellett DN
    Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.
    Pardridge WM; Casanello-Ertl D; Duducgian-Vartavarian L
    J Clin Invest; 1980 Jul; 66(1):88-93. PubMed ID: 7400311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Peroxisome induction with clofibric acid and bis(p-chlorophenoxy)acetic acid (proceedings)].
    Zipper J; Janowski K; Göres E
    Pharmazie; 1979; 34(5-6):366-7. PubMed ID: 515158
    [No Abstract]   [Full Text] [Related]  

  • 46. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 48. Stereospecificity of the chloride ion channel: the action of chiral clofibric acid analogues.
    Bettoni G; Loiodice F; Tortorella V; Conte-Camerino D; Mambrini M; Ferrannini E; Bryant SH
    J Med Chem; 1987 Aug; 30(8):1267-70. PubMed ID: 2441051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A renal mechanism for the clofibric acid-probenecid interaction.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):739-42. PubMed ID: 6655567
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacology and toxicology of etofylline clofibrate].
    Sterner W; Korn WD
    Arzneimittelforschung; 1980; 30(11b):2023-31. PubMed ID: 7194053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bezafibrate does not influence the QT interval in man.
    Olsson AG; Ekelund LG; Lang PD; Vollmar J
    J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
    [No Abstract]   [Full Text] [Related]  

  • 54. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action].
    Dănilă G; Nechifor M; Filip M; Păduraru I; Ifrim C; Grădinariu D; Papa V; Manolescu A; Bădescu A
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):127-32. PubMed ID: 3393745
    [No Abstract]   [Full Text] [Related]  

  • 55. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
    Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
    Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
    Ginocchio AV; Metz G
    Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 58. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 60. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.